REGN1979 is an investigational bispecific monoclonal antibody that binds to CD3 on immune system T-cells and to CD20
on B-cell malignancies to help trigger tumor killing.
Under the deal, Mustang Bio entered into an investigator-initiated clinical trial agreement to offer partial funding for a Phase 1/2 clinical trial at Fred Hutch, assessing the safety and efficacy of the CD20
Technology in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Most of the CHL cases are also CD15 positive whilst CD20
is positive with varied intensity in 30-40% of cases.
Leukocyte common antigen and CD20
positivity uniformly seen in DLBCL cases is usually weak to scant in PBL.
The contents of CD3 CD4 CD8 and CD20
in the stained cells of the maxillary sinus mucosal layer were calculated.
The response rate observed in this study points to the need to combine CD20
agents with cytotoxic chemotherapeutic agents in further investigations of CD20
therapy in such heavily pretreated DLBCL patient populations," said Genmab's CEO Jan van de Winkel.
The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20
that have been established pursuant to the agreement.
Like Rituxan, the experimental compound targets a type of immune cell, called CD20
that plays a role in non-Hodgkin's lymphoma.
Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope (specific binding site)of the CD20
molecule on the surface of B-cells.
(ofatumumab), a fully human monoclonal antibody, is in late stage development for CD20
positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma (NHL), and in Phase II for rheumatoid arthritis (RA).
While there is tumor individuality, the neoplastic cells usually show a B cell phenotype (CD19, CD20
, CD22, CD79a) with coexpression of CD10 and CD43; they also express bcl-2 and bcl-6 and demonstrate light-chain (kappa or lambda) restriction.
To characterize the immune response in inoculation eschars during ATBF and Mediterranean spotted fever, paraffin sections were stained with the polymorphonuclear leukocyte marker CD 15 (Immunotech, Marseille, France), the macrophage marker CD68 (Dako, Trappes, France), the T-lymphocyte marker CD3 (Dako), the B-lymphocyte marker CD20
(L26, Dako), and the endothelial cell marker Factor VIII-related antigen (Dako) by using the peroxidase-based method described above.